AlphaTON stock soars 200% after pioneering digital asset oncology initiative
Joseph Michael Fitzgerald, EVP & Group Pres, Cardiology at Boston Scientific (NYSE:BSX), sold 50,000 shares of common stock on September 2, 2025, in two transactions totaling $5.2 million.
The sales were executed at weighted average prices of $104.886 and $105.8486 per share. The first sale involved 21,830 shares sold in multiple transactions at prices ranging from $104.32 to $105.25. The second sale consisted of 28,170 shares sold in multiple transactions at prices ranging from $105.32 to $106.27.
On the same day, Fitzgerald also exercised options to acquire 50,000 shares of Boston Scientific common stock at a price of $26.15, for a total value of $1,307,500.
Following these transactions, Fitzgerald directly owns 178,342 shares of Boston Scientific stock. He also indirectly owns 5,234 shares through a child.
In other recent news, Boston Scientific reported a strong quarter with significant growth in several of its product lines. The company achieved a 17% year-over-year organic revenue increase and a 23% rise in earnings per share, outperforming market expectations. Analysts from RBC Capital, Bernstein SocGen Group, and Mizuho have raised their price targets for Boston Scientific, reflecting confidence in its performance. RBC Capital set the new target at $125, Bernstein at $130, and Mizuho at $140, each maintaining an Outperform rating. The growth was notably driven by the electrophysiology division, which saw a 94% increase due to the Farapulse product, and a 28% rise in the Watchman segment. However, the U.S. Food and Drug Administration disclosed a potentially high-risk issue with Boston Scientific’s defibrillation leads linked to patient deaths. The FDA is collaborating with the company to address concerns about the ENDOTAK RELIANCE Defibrillation leads. Despite this, analysts like Truist Securities remain optimistic, citing multiple tailwinds for the company’s future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.